Xeris to Participate in Upcoming Investor Conferences
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced its participation in three upcoming investor conferences in September 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
-
2024 Wells Fargo Healthcare Conference,
Boston, MA - Meetings only on September 4, 2024
-
H.C. Wainwright 26th Annual Global Investor Conference,
New York, NY - Meetings and fireside chat on September 10, 2024 at 3:30pm ET
-
2024 Cantor Global Healthcare Conference,
New York, NY - Meetings only on September 18, 2024
Please check with each conference sponsor to arrange 1x1 meetings.
Webcast information for the fireside chat will be available at https://xerispharma.com/investor-relations.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing differentiated and innovative products across a range of therapies. Xeris has three commercially available products: Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; Keveyis®, a proven therapy for primary periodic paralysis; and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris has a pipeline of development and partnered programs using its formulation sciences, XeriSol™ and XeriJect®, to support long-term product development and commercial success.
Xeris is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822640280/en/
Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.